CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER).

How it works

CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.

What the body does with it

Metabolism	Dextrose undergoes glycolysis and oxidation via the citric acid cycle. Amino acids are deaminated and metabolized via ureagenesis and gluconeogenesis.
Excretion	The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination.
Half-life	Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture.
Protein binding	Amino acids: variable, generally low (0-30%) bound to albumin and other plasma proteins. Dextrose: negligible protein binding. Electrolytes: calcium is ~40-50% bound to albumin and other proteins; magnesium ~30%; phosphate ~10-20%; others minimal. Overall, component-specific.
Volume of Distribution	Not applicable as a single entity. Amino acids distribute into total body water (~0.5-0.6 L/kg). Dextrose distributes into extracellular fluid (~0.2 L/kg) initially, then intracellularly. Electrolytes distribute according to their physiological compartments. No meaningful Vd for the mixture.
Bioavailability	Intravenous: 100% bioavailability as it is administered directly into the bloodstream. Not applicable to oral or other routes.
Onset of Action	Intravenous infusion: immediate upon administration. Clinical effects such as serum glucose elevation and amino acid incorporation begin within minutes. Full metabolic effects (e.g., nitrogen balance improvement) occur over hours to days with continuous infusion.
Duration of Action	Intravenous infusion: duration depends on infusion rate; continuous infusion provides sustained effect. Metabolic effects persist for several hours post-infusion as nutrients are cleared. Clinical notes: prolonged infusion (e.g., 24 hours) is typical for parenteral nutrition to maintain metabolic support.

Classification & Brands

Dosing & administration

Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.

Dosage form	INJECTABLE
Renal impairment	For GFR 30-59 mL/min: reduce volume by 25-50%; monitor electrolytes. For GFR 15-29 mL/min: reduce volume by 50-75%; avoid if severe renal impairment. For GFR <15 mL/min: contraindicated unless on renal replacement therapy; use with caution and adjust electrolytes.
Liver impairment	Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce amino acid dose by 50%; monitor ammonia. Child-Pugh Class C: avoid due to risk of hepatic encephalopathy; alternative nutrition may be needed.
Pediatric use	Dose based on weight (kg) and caloric needs. Typical: 10-15 mL/kg/day initially, titrate to 20-30 mL/kg/day. Maximum dextrose infusion rate: 0.5 g/kg/hr for neonates, 1 g/kg/hr for older children. Use with caution in low birth weight infants.
Geriatric use	Elderly patients often require lower doses due to decreased renal function; start at lower infusion rates (e.g., 1-2 mL/kg/hr). Monitor fluid balance, electrolytes, and renal function closely. Dose adjustment based on GFR is recommended.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Breastfeeding	Components are endogenous substances normally found in breast milk. Dextrose and amino acids are present in milk; no adverse effects expected. M/P ratio not established. Safe to use during breastfeeding when clinically indicated.
Teratogenic Risk	CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, but no evidence of malformations. Second and third trimesters: no known fetal risks. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose control is poor.

Warnings & precautions

■ FDA Black Box Warning

Not for intravenous infusion unless admixed with appropriate electrolytes and vitamins. Do not administer simultaneously with blood through the same infusion site because of risk of pseudoagglutination. Use with caution in patients with severe hepatic or renal disease.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Severe hyperglycemia or diabetes mellitus with ketoacidosis","Severe hepatic or renal failure (unless adjusted)","Intracranial or intraspinal hemorrhage","Anuria (for electrolyte-containing formulations)"]

Clinical Precautions

Precautions

["Monitor fluid balance, electrolyte concentrations, and acid-base status","Risk of hyperglycemia, hyperosmolarity, and metabolic acidosis","Hepatic and renal impairment require dose adjustment","Contains aluminum which may be toxic with prolonged use","Use with caution in patients with heart failure or pulmonary edema"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…